A pilot randomised controlled trial assessing the impact of sharp short bevelled catheters on first-time insertion success
A pilot randomised controlled trial assessing the impact of sharp short bevelled catheters on first-time insertion success in adult patients.
Griffith University
100 participants
Nov 11, 2025
Interventional
Conditions
Summary
Aims: To determine the feasibility of a larger study in patients with difficult intravenous access to compare short-bevelled peripheral intravenous catheters (SB-PIVCs) with standard PIVCs. Participants: 100 adult patients from medical/surgical and oncology/haematology wards. 3-4 staff PIVC inserters for process evaluation. Methods: Pilot randomised controlled trial. Patients will be randomised to have either a SB-PIVC or standard PIVC inserted to facilitate their clinical care. Patients will be visited daily by research nurses for data collection. The study will end when the PIVC is removed as clinically indicated. Small process evaluation included. Expected outcomes: It will be feasible to conduct a larger trial and first-time insertion success will be higher in the SB-PIVC group than the standard PIVC group.
Eligibility
Inclusion Criteria6
- Patient greater than or equal to 16 years
- PIVC required for greater than or equal to 24 hours
- Identified as difficult PIVC insertion by meeting at least one of the following
- a. Lack of visible and/or palpable veins
- b. Medical history of DIVA or high risk for DIVA (eg. End-stage renal disease and receiving dialysis, IV drug user, sickle cell disease etc)
- c. Prior failed PIVC insertion attempt
Exclusion Criteria4
- Veins deeper than 1 cm from skin surface
- Unable to provide informed consent
- Previous study enrolment
- End-of-life pathway
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Short bevelled peripheral intravenous catheter (SB-PIVC) (Surflo Zero, 3D-Shin®, Terumo Corporation, Tokyo, Japan) The intervention will be delivered once per patient. The intervention time period (ie. device dwell time) will be as clinically indicated. PIVCs will be followed for their entire dwell time. The SB-PIVC will be used at the recruiting hospital and inserted by hospital-credentialled research staff whilst the patient is in hospital and as clinically indicated. The device will be monitored daily for the entirety of it's dwell by research staff to assess for protocol adherence and device complications.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12625001018404